: With the introduction of newer prostaglandins, prostaglandin analogues and anti-progesterone agent Mifepristone the outcome of early 1st trimester terminations has become more safe and effective. The objective of this study was to compare between mifepristone plus misoprostol regimen and misoprostol alone regimen for second trimester termination of pregnancy.
Methods: A tertiary hospital based prospective clinical trial of 110 pregnant women between 18-45 years of age in their second trimester (13 – 20 weeks) was included in the study. After informed written consent patient enrolled was randomly allocated into two groups of 55 each. Group I where mifepristone 200 mg oral given to 55 patients on admission and after 24 hours in these cases 600mcg of misoprostol inserted vaginally and thereafter 400 mcg every 3 hr until the abortion will occur or upto a maximum 5 doses. Group II – where misoprostol only in the same schedule will be given to 55 patients.
Results: Mean maternal age ± SD was 25.85 ± 4.32 years. Commonest indication for second trimester termination was intrauterine death (50.9%) followed by gross congenital malformation incompatible with life (37.3%): anencephaly was commonest anomaly accounted for 24.45%. Mean induction-abortion (IAI) interval in group I and II was 8.81±5.75 hours & 10.81±3.42 hours respectively, which is statistically significant (p=0.02).
Conclusion: Combination of Mifepristone with Misoprostol for second trimester termination of pregnancy decreases induction-abortion interval significantly as compared to Misoprostol given alone.